<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00858546</url>
  </required_header>
  <id_info>
    <org_study_id>SHEBA-09-6874-OC-CTIL</org_study_id>
    <nct_id>NCT00858546</nct_id>
  </id_info>
  <brief_title>The Influence of Low Frequency Repetitive Transcranial Stimulation (r-TMS) Treatment on Motor and Cognitive Measurements in Patients With Parkinson's Disease</brief_title>
  <official_title>The Influence of Low Frequency Repetitive Transcranial Stimulation (r-TMS) Treatment on Motor and Cognitive Measurements in Patients With Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to test the effects of low frequency deep rTMS using the novel H-coil&#xD;
      on the motor, affective and cognitive deficits in patients with Parkinson's disease (PD) and&#xD;
      to establish its safety in this population.&#xD;
&#xD;
      The investigators anticipate to recruit 10 patients to an open pilot study. All patients will&#xD;
      receive an active rTMS stimulation and will be given 12 treatment sessions, over a period of&#xD;
      up to 4 weeks. Each of the 12 daily treatment sessions (lasting about 30 minutes each), will&#xD;
      be consisted of 25 stimulation trains over the prefrontal cortex (20Hz trains, 2 seconds each&#xD;
      with an inter-train interval of 20 seconds) and one train of 15 minutes at 1 Hz over the the&#xD;
      motor cortex.&#xD;
&#xD;
      The following outcome measures will be taken prior to the treatment (screening visit), and at&#xD;
      day 1, 10, 30, 60, and 90:&#xD;
&#xD;
        1. Unified Parkinson's Disease Rating Scale (UPDRS )&#xD;
&#xD;
        2. Clinical Global Impression of Severity (CGIS)&#xD;
&#xD;
        3. Pegboard test.&#xD;
&#xD;
        4. Tapping test&#xD;
&#xD;
        5. Up &amp; Go test&#xD;
&#xD;
        6. Abnormal Involuntary Movement Scale (AIMS) Mood and affect Beck Depression Inventory&#xD;
           (BDI) Cognition&#xD;
&#xD;
      1. Mini mental State examination (MMSE) 2. Digit forward and backward tests. 3. Word fluency.&#xD;
      4. Frontal Assessment Battery (FAB)&#xD;
&#xD;
      Side effects will be closely monitored by the researchers and will be promptly reported to&#xD;
      the IRB&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Unified Parkinson's Disease Rating Scale (UPDRS )</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>CGIS, Pegboard test,Tapping test,Up &amp; Go test, AIMS,BDI MMSE, Digit forward and backward, Word fluency, FAB</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Active repetitive transcranial Stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active repetitive transcranial Stimulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Repetitive transcranial stimulation</intervention_name>
    <description>Repetitive transcranial stimulation</description>
    <arm_group_label>Active repetitive transcranial Stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  PD patients aged 40 years or older, diagnosed as idiopathic PD according to the UK&#xD;
             Brain Bank criteria, with Hoehn &amp; Yahr stages II - IV while &quot;off&quot;.&#xD;
&#xD;
          -  Participants on antidepressants should be at least 2 months on stable therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have concomitant epilepsy, a history of seizure or heat convulsion or&#xD;
             history of epilepsy in first degree relative.&#xD;
&#xD;
          -  Patients on neuroleptics.&#xD;
&#xD;
          -  Patients with dementia or any unstable medical disorder.&#xD;
&#xD;
          -  History or current Unstable hypertension.&#xD;
&#xD;
          -  History of head injury or neurosurgical interventions.&#xD;
&#xD;
          -  History of any metal in the head (outside the mouth).&#xD;
&#xD;
          -  Known history of any metallic particles in the eye, implanted cardiac pacemaker or any&#xD;
             intracardiac lines, implanted neurostimulators, surgical clips or any medical pumps.&#xD;
&#xD;
          -  History of migraine or frequent or severe headaches.&#xD;
&#xD;
          -  History of hearing loss.&#xD;
&#xD;
          -  The presence of cochlear implants&#xD;
&#xD;
          -  History of drug abuse or alcoholism.&#xD;
&#xD;
          -  Pregnancy or not using a reliable method of birth control.&#xD;
&#xD;
          -  Participation in current clinical study or clinical study within 30 days prior to this&#xD;
             study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>October 2009</verification_date>
  <study_first_submitted>March 8, 2009</study_first_submitted>
  <study_first_submitted_qc>March 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2009</study_first_posted>
  <last_update_submitted>October 15, 2009</last_update_submitted>
  <last_update_submitted_qc>October 15, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 16, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr. Oren Cohen</name_title>
    <organization>Sheba Medical Center</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

